Madhavi Chilkuri

Dr. Madhavi Chilkuri


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2023 in Current Oncology
Verified
Journal Article
Open access
PDF file
JSJustin Smith
Justin Smith
JYJustin Yu
Justin Yu
Louisa GordonLouisa Gordon
Louisa Gordon
MCMadhavi Chilkuri
Madhavi Chilkuri
Aim: To quantify financial toxicity and out-of-pocket costs for patients with HNC in Australia and explore their relationship with health-related quality of life (HRQoL). Methods: A cross-sectional survey was administered to patients with HNC 1–3 years after radiotherapy at a regional hospital in Australia. The survey included questions on sociodemographics, out-of-pocket expenses, HRQoL, and the Financial Index of Toxicity (FIT) tool. The relationship between high financial toxicity scores (top quartile) and HRQoL was explored. Results: Of the 57 participants included in the study, 41 (72%) reported out-of-pocket expenses at a median of AUD 1796 (IQR AUD 2700) and a maximum of AUD 25,050. The median FIT score was 13.9 (IQR 19.5) and patients with high financial toxicity (n = 14) reported poorer HRQoL (76.5 vs. 114.5, p < 0.001). Patients who were not married had higher FIT scores (23.1 vs. 11.1, p = 0.01), as did those with lower education (19.3 vs. 11.1, p = 0.06). Participants with private health insurance had lower financial toxicity scores (8.3 vs. 17.6, p = 0.01). Medications (41%, median AUD 400), dietary supplements (41%, median AUD 600), travel (36%, median AUD 525), and dental (29%, AUD 388) were the most common out-of-pocket expenses. Participants living in rural locations (≥100 km from the hospital) had higher out-of-pocket expenses (AUD 2655 vs. AUD 730, p = 0.01). Conclusion: Financial toxicity is associated with poorer HRQoL for many patients with HNC following treatment. Further research is needed to investigate interventions aimed at reducing financial toxicity and how these can best be incorporated into routine clinical care.

17 April 2025 in Cancers
Verified
Journal Article
Open access
PDF file
KFKylie Lopes Floro
Kylie Lopes Floro
RGRhys Gillman
Rhys Gillman
MWMiriam Wankell
Miriam Wankell
BDBrittany Dewdney
Brittany Dewdney
MCMadhavi Chilkuri
Madhavi Chilkuri
LHLionel Hebbard
Lionel Hebbard
Background/Objectives: Smokers are at an increased risk of developing mucosal head and neck squamous cell cancers (HNSCCs) and have a worse prognosis when treated. The cellular and molecular mechanisms underlying the latter has not been established. We therefore developed an in vitro model to investigate the effects of radiation and smoking on mucosal HNSCCs. FaDu hypopharyngeal cancer cells were subjected to daily fractionated radiation and cultured with and without cigarette-smoke-exposed media. Methods: The cells were characterised using assays for tumour sphere formation, proliferation, migration, invasion, CD44 and ALDH expression, and next generation sequencing. We also evaluated CD44 and ALDH1 expression in patient tumour samples. Results: Radiation and smoking separately reduced FaDu tumour sphere/Cancer Stem Cell (CSC) number and proliferation, and increased cell migration and invasion. Combined, they further reduced CSC number proliferation and promoted migration. CD44 and ALDH co-expression was reduced in conditions with cigarette smoke. Through next generation sequencing, radiation and smoking produced a gene signature related to cell invasion, angiogenesis, and survival. Immunohistochemistry for CD44 and ALDH1 on patient tumour specimens did not demonstrate a relationship with smoking status, supported our in vitro findings. Conclusions: The data show the utility of a new experimental model to test the combination of radiation and smoking on mucosal HNSCCs behaviour.